A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy

Mov Disord. 2007 Aug 15;22(11):1664-6. doi: 10.1002/mds.21631.

Abstract

X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disorder caused by a mutation in the Bruton agammaglobulinemia tyrosine kinase gene that results in severe B-cell deficiency. So far, neurological complications of XLA have been primarily related to acute and/or chronic central nervous system enteroviral infections. In the last few years a progressive neurodegenerative syndrome of unknown etiology has been described in XLA patients. We describe and present a video of an XLA patient who developed a fatal dementing, dystonia-Parkinsonism syndrome 14 years into his immune disorder. Physician awareness of this rare syndrome may lead to its better characterization and management.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Brain / pathology
  • Dystonic Disorders / complications
  • Dystonic Disorders / drug therapy*
  • Dystonic Disorders / pathology
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Magnetic Resonance Imaging / methods
  • Male
  • Parkinsonian Disorders / complications
  • Parkinsonian Disorders / drug therapy*
  • Parkinsonian Disorders / pathology
  • X-Linked Combined Immunodeficiency Diseases / complications
  • X-Linked Combined Immunodeficiency Diseases / drug therapy*
  • X-Linked Combined Immunodeficiency Diseases / pathology

Substances

  • Immunoglobulins, Intravenous
  • Immunologic Factors